GENOMIC BLOOD TEST

 

Identify your patient’s actionable lung cancer mutations

Guideline-recommended, blood-based mutation results within 72 hours.

 

What is the GeneStrat® test?

  • Delivers guideline-recommended1, blood-based mutation results: EGFR, ALK, ROS1, RET, BRAF, and KRAS
  • Results within 72 hours can reduce treatment delays and expedite clinical trial enrollment
  • Drives treatment strategy and facilitates monitoring
DOWNLOAD TEST REPORT  

Testing Platform

  • Measures circulating cell-free DNA and RNA using Droplet Digital PCR (ddPCR)
  • Highly sensitive and specific mutation detection
  • Clinically validated
LEARN MORE  
THE GENES TESTED IN THE GENESTRAT® TEST ARE COVERED BY MEDICARE AND MANY PRIVATE PAYERS.

Nearly 80% of patients currently do not have mutation results available at their initial oncology consult.
How do we change this paradigm with blood-based testing?

Source: Lim, C., et.al. 2015. Biomarker Testing and Time to Treatment Decision in Patients with Advanced Non-Small Cell Lung Cancer. Ann Oncol first published online April 28, 2015

Save time

BLOOD-BASED RESULTS WITHIN 72 HOURS EXPEDITE TIME TO TREATMENT IN AS

LITTLE AS 8 DAYS2 FROM DIAGNOSTIC BIOPSY.

Tissue-based Tumor Mutation Testing: Presentation to Treatment

GeneStrat Tumor Mutation Testing: Presentation to Treatment

Reference: 1. NCCN Guidelines 2. Bowling, et al. J Clin Oncol 36, 2018 (suppl; abstr e18519) 3. Hagemann, et al. Cancer. 2015;121:631-9. 4. Vidaver RM et al. J Oncol Pract 2016 Jun 3;12(6):e643-53

 

 

Complement Your Molecular Testing Strategy

Reference: Boyle T, et al. Poster presentation: AMP annual meeting. Salt Lake City, UT; 2017.

 

Accurate, actionable genomic results

SEE DATA  

Interested in ordering a test kit?

REQUEST KIT    

Get in touch

Contact us